Drug approvals by the US FDA’s Center for Drug Evaluation and Research reached a 15-year high last year, growing 33% to 39 new drugs, and consisting of 33 new molecular entities, up from 24 in 2011, and 6 new biological entities, the same as a year ago. Twenty of the drugs were first in-class agents. […]
Global investments in clean energy declined 11% last year to $268.7 billion. Countries where investments showed the fastest growth included China, the largest investor, where they increased 20% to $67.7 billion; and Japan, where they jumped 75% to $16.3 billion (excluding R&D). US, German and Brazilian investments plunged 32%, 27% and 32% to $44.2 billion, […]
As the analytical instrument and lab product industry grows, so do companies’ interest in it. Last year, Ahlstrom and Pentair were among the multimillion-dollar companies that increased their industry presence. Both firms serve a variety of markets based on their core focuses. In the case of Ahlstrom, its focus is fiber-based materials. Pentair’s core focus […]
The US FDA released proposals earlier this month for two new food safety rules as part of the Food Safety Modernization Act. The first rule, “Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventive Controls for Human Food,” would require firms handling food to have written plans identifying hazards and how to address them, […]
US R&D grew 1.8% to $414.0 billion in 2011, according to preliminary estimates. But, in constant dollars, the amount, as in the previous two years, is below 2008 levels. Also, as in 2010, R&D grew slower than GDP in 2011. Business funded 60% of US R&D activities in 2011, a 0.1% increase, and performed 69%, […]
The US Congress passed legislation in early January temporarily delaying automatic federal budget cuts until March 1. It is estimated that the fiscal 2013 cuts would have eliminated 2,500 NIH grants and 1,500 NSF grants. However, research funding remains vulnerable. The new agreement only lowers the required cuts for fiscal 2013 from $361 billion to […]
Overview Life science industries continue to be the instrument and lab product market growth leaders. However, the agriculture/food market is estimated to offer slightly greater sales opportunities this year than pharmaceutical labs, as contamination issues are a growing global problem. Both pharmaceutical and biotechnology segments, along with their support counterparts, CROs, will have above average […]
This month, the EPA released final amendments to clean air standards for industrial boilers and certain incinerators, as well as a new definition of nonhazardous secondary materials. Of the 1.5 million boilers in the US, less than 1% will need to meet numerical emission limits, which differ among the different subcategories of boilers, and 13% […]
According to a new estimate by the UK’s Office of Health Economics based on 2002 and 2003 confidential CMRI surveys, the average R&D cost of a medicine is $1.5 billion (in 2011 prices). The four primary variables affecting the cost are out-of-pocket costs, success rates, development times and cost of capital. The cost of capital […]
Global R&D spending is forecast to increase 1.8% to $1,496.4 billion in 2013, measured in purchase powered parity, down from 5.2% growth. R&D expenditures in the life sciences, chemicals and energy sectors are expected to increase 4.2%, 0.6% and 1.6% to account for 13%, 3% and 1% of worldwide R&D spending, respectively. R&D spending is […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
